A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
15/02/2022at 15:18

Analyst ahead of Genmab report: Focus will be on Darzalex prognosis

Genmab’s 2022 guidance will take center stage when the company presents its full-year financial report on Wednesday.
Photo: Joost Melis / Genmab / PR
by marketwire, translated by daniel pedersen

Some of the excitement has been taken out of Genmab’s full-year financial report, which will be publicized on Wednesday. The company’s partner Johnson & Johnson has already published figures for Genmab’s biggest source of revenue, cancer drug Darzalex.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Tuala Hjarnø / Genmab / PR

    Janssen submits Genmab-developed drug for EMA approval

    For subscribers

  • Photo: Tuala Hjarnø / Genmab / PR

    Genmab: Darzalex sales in line with expectations

    For subscribers

  • Photo: Genmab

    Anthony Mancini will help Genmab take its next steps

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Janssen is the pharmaceutical arm of Johnson & Johnson | Foto: Mike Blake
Pharma & biotech

Janssen's books disappointing sales of Genmab-developed Darzalex

Fourth-quarter sales figures from cancer drug Darzalex, which was developed by Danish biotech company Genmab, did not meet analysts’ expectations.

For subscribers

Foto: Bavarian Nordic / Pr
Pharma & biotech

Analyst: Bavarian has even better year ahead after breakeven 2022

An analyst think it’s likely that the Danish vaccines maker has executed early on some deliveries planned for 2023, securing a better-than-expected financial performance in 2022.

For subscribers

Pharma & biotech

GlobalData predicts huge diabetes market growth, names Novo Nordisk drugs as drivers

The type 2 diabetes treatment market will triple in size over ten years, according to the analysis firm’s estimations.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Lead Data Architect

  • Clinical Operational Associate

  • Application Manager

  • Principal Laboratory Technologist

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Commercial Director

See all jobs

Jobs

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Lead Data Architect

  • Clinical Operational Associate

  • Application Manager

  • Principal Laboratory Technologist

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Commercial Director

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge